Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HEXA | P06865 | 1/20 | 0.41 |
| ▸ | HEXB | P07686 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29556018 | 0.98 | GAA (0.67) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| Hydrochloric Acid SCHEMBL5418885 | 0.98 | GAA (0.67) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| SCHEMBL14237867 | 0.89 | GAA (0.83) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| SCHEMBL2538210 | 0.89 | GAA (0.65) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| SCHEMBL22326350 | 0.87 | GAA (0.88) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| Trifluoroacetic Acid SCHEMBL22382472 | 0.86 | GAA (0.53) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| SCHEMBL17264136 | 0.85 | GAA (0.61) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| SCHEMBL30779744 | 0.84 | GAA (0.69) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| SCHEMBL8544461 | 0.84 | GAA (0.69) | GAAALDH1A1CYP1A2RECQLKMT2A | |
| SCHEMBL13108193 | 0.83 | GAA (0.62) | GAAALDH1A1CYP1A2RECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778609-B1 | PENAM DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | FUJIFILM CORP (JP) | 2022-01-26 | — | — | EP | disclosed |
| EP-3154997-B9 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3778609-A1 | NOVEL PENAM DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | FUJIFILM Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20210024543-A1 | NOVEL PENAM DERIVATIVE OR SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2021-01-28 | — | — | US | disclosed |
| US-10696707-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3154997-B1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2020-01-28 | — | — | US | disclosed |
| WO-2019194306-A1 | NOVEL PENAM DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 富士フイルム株式会社 | 2019-10-10 | — | — | WO | disclosed |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NR0B1, NR2E1, NR0B2 | GAA 1099/4885ALDH1A1 1128/4885CYP1A2 397/4885 |
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | MAPK9, MAPK4, MAPK1 | GAA 3904/4885ALDH1A1 1196/4885CYP1A2 1478/4885 |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | GAA 448/4885ALDH1A1 4446/4885CYP1A2 2284/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | GAA 3106/4885ALDH1A1 1140/4885CYP1A2 1634/4885 |
| US-20210024543-A1 | NOVEL PENAM DERIVATIVE OR SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | CFTR, SLC11A2, SLC20A1 | GAA 366/4885ALDH1A1 3443/4885CYP1A2 4378/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | GAA 512/4885ALDH1A1 3229/4885CYP1A2 4735/4885 |
| US-10696707-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | GAA 448/4885ALDH1A1 4446/4885CYP1A2 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.